Head and Neck Squamous Cell Carcinoma
The sponsor’s research is centered on head and neck squamous cell carcinoma, with a focus on locally advanced disease requiring definitive radiotherapy and cisplatin-based treatment.
- Locally advanced head and neck cancer
- Definitive radiotherapy
- Cisplatin-based treatment
Its clinical activity reflects interest in treatment strategies for patients with locally advanced head and neck squamous cell carcinoma, including those who are unable to receive cisplatin.
DNA Damage Response and Immunotherapy
Another area of interest is the combination of niraparib, a PARP inhibitor, with dostarlimab, an immune checkpoint inhibitor, in the management of head and neck cancer.
- PARP inhibition
- Immune checkpoint blockade
- Neoadjuvant and adjuvant treatment use
The sponsor is engaged in therapeutic approaches that integrate DNA repair targeting with immunotherapy across peri-treatment settings.
Post-Platinum and Post-Pembrolizumab Disease
The sponsor also studies treatment options for recurrent or metastatic squamous cell carcinoma of the head and neck after prior exposure to pembrolizumab and platinum-based chemotherapy.
- Recurrent disease
- Metastatic disease
- After checkpoint inhibitor therapy
This includes interest in therapies used after progression on standard systemic regimens in advanced head and neck squamous cell carcinoma.
Cetuximab-Based Therapy
Research activity extends to cetuximab-based treatment, including use with paclitaxel or as monotherapy in advanced head and neck squamous cell carcinoma.
- Cetuximab combinations
- Paclitaxel
- Monoclonal antibody therapy
This area addresses systemic treatment choices for patients with disease progression following prior immunotherapy and chemotherapy.
